Betrixaban
Chemical compound / From Wikipedia, the free encyclopedia
Betrixaban (trade name Bevyxxa) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor.[1] Betrixaban is FDA approved for venous thrombosis prevention in adults hospitalized for an acute illness who are at risk for thromboembolic complications.[2] Compared to other directly acting oral anticoagulants betrixaban has relatively low renal excretion and is not metabolized by CYP3A4.[3]
This article needs more reliable medical references for verification or relies too heavily on primary sources. (November 2018) |
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Bevyxxa |
Other names | PRT054021, PRT064445 |
AHFS/Drugs.com | bevyxxa |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 60% |
Elimination half-life | 19–27 hrs |
Duration of action | ≥72 hrs |
Excretion | 85% feces, 11% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.746 |
Chemical and physical data | |
Formula | C23H22ClN5O3 |
Molar mass | 451.91 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close